Dr. Reddy's Laboratories Limited (BOM:500124)
India · Delayed Price · Currency is INR | Market Cap | 997.15B |
| Revenue (ttm) | 342.15B |
| Net Income (ttm) | 58.62B |
| Shares Out | 832.52M |
| EPS (ttm) | 70.30 |
| PE Ratio | 17.04 |
| Forward PE | 18.90 |
| Dividend | 8.00 (0.67%) |
| Ex-Dividend Date | Jul 10, 2025 |
| Volume | 84,483 |
| Average Volume | 311,657 |
| Open | 1,201.30 |
| Previous Close | 1,202.15 |
| Day's Range | 1,190.60 - 1,205.90 |
| 52-Week Range | 1,025.90 - 1,404.60 |
| Beta | 0.33 |
| RSI | 33.92 |
| Earnings Date | Oct 31, 2025 |
About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages i... [Read more]
Financial Performance
In 2024, Dr. Reddy's Laboratories's revenue was 325.54 billion, an increase of 16.61% compared to the previous year's 279.16 billion. Earnings were 56.54 billion, an increase of 1.54%.
Financial StatementsNews
Dr. Reddy's Laboratories Becomes Oversold (RDY)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
Dr. Reddy’s Laboratories shares fall over 4% after delay in Semaglutide approval in Canada
Dr. Reddy’s Laboratories’ shares fell more than 4% in early trade on Thursday, October 30, after the company announced a...
Dr. Reddy's: Underappreciated Future Amid Exaggerated Headwinds
Dr. Reddy's Laboratories remains a compelling buy due to underappreciated growth in biosimilars and GLP-1 segments, despite near-term headwinds. RDY's Q2 FY26 results showed modest revenue growth, wit...
RDY Crosses Below Key Moving Average Level
In trading on Wednesday, shares of Dr. Reddy's Laboratories Ltd. (Symbol: RDY) crossed below their 200 day moving average of $14.14, changing hands as low as $13.42 per share. Dr. Reddy's Laboratories...
Nifty 50 top losers today, October 29: Dr. Reddy’s Laboratories, Coal India, Bharat Electronics, Eternal and more
Indian equity benchmarks ended higher on October 29, with the Nifty closing above the 26,000 mark. The Sensex gained 368.97...
Why Indian pharma giant Dr Reddy's is unfazed by Trump's tariff threats
Dr Reddy's CEO Erez Israeli says the pivot is already visible - India and Europe growth is now driven by innovation, consumer health and branded products, not just U.S. generics.
Dr Reddy's Laboratories Ltd (RDY) (Q2 FY26) Earnings Call Highlights: Navigating Growth Amidst ...
Dr Reddy's Laboratories Ltd (RDY) (Q2 FY26) Earnings Call Highlights: Navigating Growth Amidst Market Challenges
Half Year 2026 Dr Reddy's Laboratories Ltd Earnings Call Transcript
Half Year 2026 Dr Reddy's Laboratories Ltd Earnings Call Transcript
Nuvama positive on Dr. Reddy’s, highlights strong Q2 beat and focus on semaglutide approval
Nuvama Institutional Equities has maintained its buy rating on Dr. Reddy’s Laboratories with a target price of ₹1,475 per share...
Dr. Reddy's Laboratories Q2 Profit Rises
(RTTNews) - Dr. Reddy's Laboratories Ltd. (ROY) reported, under IFRS standards, that its second quarter profit attributable to equity holders of the parent company increased to INR 14.37 billion or IN...
Dr. Reddy's Laboratories Limited (RDY) Q2 2026 Earnings Call Transcript
Dr. Reddy’s Laboratories Q2 Results: Revenue rises 9.8% YoY to Rs 8,805 crore, net profit up 14%
Dr. Reddy’s Laboratories today announced its consolidated financial results for the quarter and half year ended September 30, 2025. The...
Top Q2 results today, October 24: Dr. Reddy’s Laboratories, Coforge, SBI Cards, ITC Hotels and more to announce earnings
Nearly two dozen companies are set to declare their financial results for the second quarter of FY2025-26 on Thursday, October...
Dr. Reddy’s Laboratories receives EIR from USFDA for Srikakulam facility
Dr. Reddy’s Laboratories has announced an important update regarding its formulations manufacturing facility, FTO 11, located in Srikakulam, Andhra Pradesh,...
Nifty 50 top losers today, October 14: Tata Motors, Dr. Reddy’s, Bharat Electronics, Bajaj Finance, TCS, Tata Steel and more
Indian equity markets closed lower on October 14, with the Nifty ending below 25,200 amid broad-based selling. The Sensex fell...
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs
The Trump administration is reportedly planning to exclude imported generic drugs from tariffs. White House spokesman Kush Desai told the Wall Street Journal that "the administration is not actively d...
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
Bullish Two Hundred Day Moving Average Cross - RDY
In trading on Monday, shares of Dr. Reddy's Laboratories Ltd. (Symbol: RDY) crossed above their 200 day moving average of $14.22, changing hands as high as $14.23 per share. Dr. Reddy's Laboratories L...
ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up
Esperion settles Nexletol and Nexlizet patent dispute with Dr. Reddy's, securing U.S. market exclusivity until 2040 and lifting its shares nearly 14%.
Esperion Therapeutics (ESPR) Settles Patent Dispute with Dr. Reddy's
Esperion Therapeutics (ESPR) Settles Patent Dispute with Dr. Reddy's
Esperion settles patent dispute with Dr. Reddy’s over cholesterol drugs
Esperion settles with Dr. Reddy’s, delaying generic NEXLETOL/NEXLIZET until 2040.
Dr. Reddy's (RDY) Reaches Settlement in Patent Dispute with Esperion
Dr. Reddy's (RDY) Reaches Settlement in Patent Dispute with Esperion
Nifty 50 top losers today, September 29: Axis Bank, Maruti Suzuki, Dr. Reddy’s Laboratories, Adani Enterprises, HDFC Life and more
Indian equity markets closed marginally lower on September 29 after a volatile session. The Sensex slipped 61.52 points, or 0.08%, to 80,364.94, while the Nifty 50 fell 19.80 points, or 0.08%, to 24,6...
Trump’s 100% tariffs on branded drugs: Which Indian pharma stocks are most vulnerable? Experts weigh in
Donald Trump's tariff move impacts Indian pharma stocks. Companies like Sun Pharma, Cipla, and Dr. Reddy's face potential declines. US represents a major market for Indian exports.
Dr. Reddy’s shares slip over 2% as Trump’s 100% pharma tariff triggers sector-wide selloff
Shares of Dr. Reddy’s Laboratories fell 2.09% to ₹1,248.10 on Friday, as the broader pharmaceutical sector came under pressure following U.S. President Donald Trump’s announcement of a 100% tariff on ...